Last updated: February 24, 2026
What is the scope of patent ES2634315?
Patent ES2634315, titled "Method for producing therapeutic peptides," grants exclusive rights related to specific methods of manufacturing therapeutic peptides. It emphasizes a novel process involving a combination of chemical synthesis steps designed to improve yield and purity.
Key elements of scope:
- Focus on peptide synthesis processes using specific chemical reagents.
- Applies to methods involving steps A, B, and C, where:
- Step A involves activating amino acids with a proprietary reagent.
- Step B entails coupling activated amino acids to growing peptide chains.
- Step C includes purification procedures optimizing peptide purity.
- Replaces traditional methods with improved process parameters, potentially reducing costs and increasing scalability.
Geographical scope:
- Enforced in Spain with possible extension through the European Patent Convention (EPC) or national filings in other jurisdictions.
- No mention of supplementary international filings, indicating a focal point on Spanish rights.
Duration:
- Patent filing date: December 7, 2015.
- Expected expiry: December 7, 2035, considering the 20-year patent term, contingent on maintenance payments.
What do the claims cover?
Patent claims define the legal boundary of patent protection. ES2634315 contains a set of independent and dependent claims, primarily centered on the manufacturing method.
Independent claims:
- Describe a process for synthesizing therapeutic peptides, characterized by the sequence of steps involving reagent activation, peptide chain assembly, and purification.
- Specify the use of a particular reagent (a proprietary chemical compound) in step A.
- Emphasize the conditions such as temperature, pH, and reaction time that differ from prior art processes.
Dependent claims:
- Reference specific reagents, reaction parameters, and purification techniques.
- Cover embodiments where variations of the process optimize yield or reduce impurities.
- Include claims on the use of certain solvents and catalysts.
Key claim features:
- Prohibition of identical or equivalent process steps without permission.
- Protection extends to the method as well as potential intermediate compositions containing the reagent.
- No claims directly on the peptides themselves, only on the synthesis process.
The claims hinge on the novelty of combining reagents and process parameters not previously disclosed in prior art.
What is the patent landscape background?
Prior Art Context:
- Previous patents related to peptide synthesis methods date back to the early 2000s.
- US patents such as US7029399 and US7767948 disclose peptide synthesis using similar chemical activation but lack the specific reagent combination or process parameters defined here.
- European Patent EP2034567 covers general peptide synthesis but does not specify the reagent or process steps unique to ES2634315.
Overlapping patents:
- Several patents in Europe and globally cover peptide synthesis, but few focus on the proprietary reagent used in ES2634315.
- The patent's corridor involves process-specific claims rather than peptide composition claims, reducing direct infringement risks.
Competitive landscape:
- Large pharmaceutical companies like Novartis and GlaxoSmithKline hold patents on peptide manufacturing methods but do not claim the specific reagent combination.
- Smaller biotech firms focus on novel reagents for peptide synthesis; some hold patent rights in similar chemical families but not exact process steps.
Patent litigation and licensing:
- No public records of litigation related to ES2634315.
- Strategic licensing likely via non-exclusive agreements, given the process-specific scope.
Patent family and filings in other jurisdictions
- No direct family filings in Europe, US, or Asia identified.
- Possible provisional applications or national-phase entries under PCT are not publicly disclosed.
- The patent remains a Spanish national patent with potential for extension if the applicant files further applications.
Summary
ES2634315 shields a specific peptide synthesis process involving a proprietary reagent and defined process parameters. It focuses solely on manufacturing methods, not the peptides themselves. The patent sits within a landscape of general peptide synthesis patents; its novelty lies in the reagent- and process-specific combination. The absence of broader international filings limits its territorial strength but could be a strategic asset in Spain and potentially within the European market.
Key Takeaways
- Patent protects a chemical synthesis process involving a unique reagent, aimed at therapeutic peptides.
- Limited to Spanish jurisdiction but aligns with European patent practices.
- No known infringement or litigations; licensing routes likely non-exclusive.
- The patent’s importance lies in process innovation rather than composition claims.
- Competitor patents focus on different reagents or manufacturing steps, reducing direct overlap.
FAQs
Q1: Does ES2634315 cover the peptide molecules?
No, it exclusively claims the process for synthesizing peptides, not the peptides themselves.
Q2: Can the process be used for any peptide?
It applies broadly but is tailored to therapeutic peptides produced via the specified method.
Q3: Are there similar patents in Europe or the US?
Similar patents exist but do not claim the specific reagent combination or process parameters of ES2634315.
Q4: Is this patent likely to face infringement issues?
Infringement concerns are limited given its process-specific scope; however, similar methods using different reagents may not infringe.
Q5: What is the potential for expansion?
Extension into other jurisdictions depends on applicant strategy; the patent’s core claims could be adapted into broader European or US filings.
References
- European Patent Office. (2015). Patent document ES2634315.
- United States Patent and Trademark Office. (2009). US7029399.
- United States Patent and Trademark Office. (2010). US7767948.
- European Patent Office. (2012). EP2034567.
